KPTI
Karyopharm Therapeutics Inc. · Healthcare · Market cap $10.9M
Insiders sold $3K net in the last 90 days ·2 sellers, 0 buyers· latest Form 4 filed Oct 19, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$351K
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Oct 19, 2026
Abate Kristin
Karyopharm Therapeutics Inc. (KPTI) has 33 SEC Form 4 filings (40 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Oct 19, 2026.
Inside the rolling window, 7 insiders at Karyopharm Therapeutics Inc. reported no open-market purchases and 21 open-market sales totaling $351K. The most active filer is Chief Accounting Officer Abate Kristin with 7 filings. The most recent open-market filing is a sale of 4,788 shares by Chief Accounting Officer Abate Kristin, dated Oct 16, 2026, worth $2K.
- Industry:Biotechnology
- CEO:Richard A. Paulson
- Employees:228
- HQ:Newton, MA, US
- IPO:2013-11-06
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Accounting Officer | Sale | 4,788 | $2K | Oct 19 | +38.7% | SEC ↗ | |
| Chief Accounting Officer | Sale | 378 | $450 | Oct 2 | -40.2% | SEC ↗ | |
Abate KristinFirst in 4 months | Chief Accounting Officer | Sale | 19 | $38 | Sep 2 | -73.2% | SEC ↗ |
| EVP, Chief Development Officer | Sale | 189 | $1K | Jul 30 | -93.2% | SEC ↗ | |
| EVP & Chief Medical Officer | Sale | 408 | $4K | May 15 | -93.7% | SEC ↗ | |
| EVP, CLO&Secretary | Sale | 266 | $3K | May 15 | -93.7% | SEC ↗ | |
| EVP, Chief Development Officer | Sale | 403 | $4K | May 15 | -93.7% | SEC ↗ | |
| Chief Accounting Officer | Sale | 53 | $504 | May 15 | -93.7% | SEC ↗ | |
| President and CEO | Sale | 2,203 | $21K | May 15 | -93.7% | SEC ↗ | |
| EVP & Chief Commercial Officer | Sale | 324 | $3K | May 15 | -93.7% | SEC ↗ | |
| EVP & Chief Medical Officer | Sale | 449 | $4K | Apr 22 | — | SEC ↗ | |
Rangwala ReshmaFirst filing | EVP & Chief Medical Officer | Sale | 5,066 | $48K | Mar 3 | — | SEC ↗ |
Paulson Richard A.First filing | President and CEO | Sale | 12,361 | $116K | Mar 3 | — | SEC ↗ |
| Chief Accounting Officer | Sale | 559 | $5K | Mar 3 | — | SEC ↗ | |
Cheng Sohanya RoshanFirst filing | EVP & Chief Commercial Officer | Sale | 4,604 | $43K | Mar 3 | — | SEC ↗ |
Mano MichaelFirst filing | EVP, CLO&Secretary | Sale | 3,526 | $33K | Mar 3 | — | SEC ↗ |
| EVP, Chief Development Officer | Sale | 5,101 | $48K | Mar 3 | — | SEC ↗ | |
Poulton StuartFirst filing | EVP, Chief Development Officer | Sale | 378 | $3K | Feb 19 | — | SEC ↗ |
Macomber LoriFirst filing | EVP, CFO & Treasurer | Sale | 1,626 | $10K | Feb 4 | — | SEC ↗ |
| Chief Accounting Officer | Sale | 50 | $352 | Jan 29 | — | SEC ↗ | |
Abate KristinFirst filing | Chief Accounting Officer | Sale | 265 | $2K | Jan 22 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does KPTI have?
Karyopharm Therapeutics Inc. (KPTI) has 33 SEC Form 4 filings (40 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Oct 19, 2026.
When was the most recent SEC Form 4 filing for KPTI?
The most recent Form 4 filing for KPTI on Tracefour is dated Oct 19, 2026.
Who is the most active insider at KPTI?
The most active SEC Form 4 filer at KPTI in the rolling window is Chief Accounting Officer Abate Kristin, with 7 filings.
What is the net insider flow at KPTI over the last 6 months?
Over the trailing 180 days, insiders at KPTI have net sold $42K based on SEC Form 4 disclosures.
What is the total insider buy and sell value at KPTI in the current window?
Inside the rolling window, insiders at KPTI bought $0 and sold $351K based on SEC Form 4 filings.
Can I get alerts for KPTI insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Karyopharm Therapeutics Inc. (KPTI). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Karyopharm Therapeutics Inc. is in the Healthcare sector.